Literature DB >> 19455130

Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus.

Chia-Ming Chu1, Yun-Fan Liaw.   

Abstract

OBJECTIVES: Most hepatitis B virus (HBV) carriers are incidentally identified as inactive carriers (positive hepatitis B e antibody with normal alanine aminotransferase (ALT) levels), but their long-time outcome and risk of cirrhosis are incompletely understood.
METHODS: A total of 1,965 inactive carriers (mean age: 35.6 years; males: 1,076) were studied. Cirrhosis was diagnosed using a high-resolution real-time ultrasound.
RESULTS: During an 11.5-year mean follow-up, 314 carriers developed reactivation of hepatitis B (ALT was more than twice the upper limit of normal and positive HBV DNA was found using hybridization assays). The risk of reactivation of hepatitis B correlated significantly with advanced age at study entry (P<0.0001) and male sex (P<0.0001). A total of 57 patients developed cirrhosis, with the cumulative incidence being 15% after 25 years. The risk of cirrhosis correlated significantly with advanced age at entry (P=0.004) and reactivation of hepatitis B (P<0.0001). Of the 1,651 carriers without reactivation of hepatitis B, 10 developed cirrhosis, and advanced age at entry was the only significant factor (P=0.03). Of the 314 patients with reactivation of hepatitis B, cirrhosis developed in 47 of them, with the cumulative incidence being 8, 16, 27, and 46% at 5, 10, 15, and 20 years, respectively, after the onset of reactivation. Male sex (P=0.037) and advanced age at reactivation (P=0.006) were the two independent risk factors.
CONCLUSIONS: The so-called inactive carrier state cannot be generally viewed as an innocent long-lasting condition of good prognosis; regular follow-up is necessary.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19455130     DOI: 10.1038/ajg.2009.187

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  29 in total

1.  Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma.

Authors:  Chia-Ming Chu; Chen-Chun Lin; Shi-Ming Lin; Deng-Yn Lin; Yun-Fan Liaw
Journal:  Dig Dis Sci       Date:  2011-08-12       Impact factor: 3.199

2.  Characteristics of chronic hepatitis B patients who underwent liver biopsies.

Authors:  W Chotiyaputta; B Degertekin; B J McKenna; N Samala; R J Fontana; A S F Lok
Journal:  J Viral Hepat       Date:  2010-08-17       Impact factor: 3.728

3.  Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010.

Authors:  Rania A Tohme; Lisa Bulkow; Chriss E Homan; Susan Negus; Brian J McMahon
Journal:  J Clin Virol       Date:  2013-08-16       Impact factor: 3.168

4.  Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a.

Authors:  Ming-Hui Li; Yao Xie; Lu Zhang; Yao Lu; Ge Shen; Shu-Ling Wu; Min Chang; Cai-Qin Mu; Lei-Ping Hu; Wen-Hao Hua; Shu-Jing Song; Shu-Feng Zhang; Jun Cheng; Dao-Zhen Xu
Journal:  World J Hepatol       Date:  2016-05-28

5.  The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study.

Authors:  Takashi Taida; Makoto Arai; Tatsuo Kanda; Shuhei Hige; Yoshiyuki Ueno; Fumio Imazeki; Namiki Izumi; Eiji Tanaka; Noboru Shinkai; Kentaro Yoshioka; Yasunari Nakamoto; Shuhei Nishiguchi; Masataka Tsuge; Masanori Abe; Michio Sata; Hiroshi Yatsuhashi; Akio Ido; Kazuhiko Kita; Ryousaku Azemoto; Yoshio Kitsukawa; Nobuaki Goto; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2016-06-15       Impact factor: 7.527

Review 6.  Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach.

Authors:  Robério Amorim de Almeida Pondé
Journal:  Mol Biol Rep       Date:  2020-12-09       Impact factor: 2.316

7.  Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients.

Authors:  Xu-Dong Liu; Jian-Lin Wu; Jian Liang; Tao Zhang; Qing-Shou Sheng
Journal:  World J Gastroenterol       Date:  2012-06-14       Impact factor: 5.742

8.  Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.

Authors:  Yuanxi Jia; Li Li; Fuqiang Cui; Dongliang Zhang; Guomin Zhang; Fuzhen Wang; Xiaohong Gong; Hui Zheng; Zhenhua Wu; Ning Miao; Xiaojin Sun; Li Zhang; Jingjing Lv; Feng Yang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  Screening and diagnosis of HBV in low-income and middle-income countries.

Authors:  Jean-Pierre Allain; Ohene Opare-Sem
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

Review 10.  Current hepatitis B treatment guidelines and future research directions.

Authors:  Jonathan Skupsky; Ke-Qin Hu
Journal:  Front Med       Date:  2014-05-29       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.